Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative efficacy of ofatumumab versus oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons.
Riley N, Drudge C, Nelson M, Haltner A, Barnett M, Broadley S, Butzkueven H, McCombe P, Van der Walt A, Wong EOY, Merschhemke M, Adlard N, Walker R, Samjoo IA. Riley N, et al. Among authors: samjoo ia. Ther Adv Neurol Disord. 2024 Mar 23;17:17562864241239453. doi: 10.1177/17562864241239453. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 38525490 Free PMC article.
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T, Usmani SZ, Schecter JM, Roccia T, Jackson CC, Deraedt W, Yeh TM, Banerjee A, Pacaud L, Garrett A, Bartlett M, Haltner A, Van Sanden S, Diels J, Valluri S, Samjoo IA. Martin T, et al. Among authors: samjoo ia. Curr Med Res Opin. 2023 Jan;39(1):81-89. doi: 10.1080/03007995.2022.2139052. Epub 2022 Nov 15. Curr Med Res Opin. 2023. PMID: 36271807
Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
Samjoo IA, Klotz L, Giovannoni G, Drudge C, Haltner A, Worthington E, Zhao M, Brennan R, Häring DA, Cameron C, Adlard N. Samjoo IA, et al. Mult Scler Relat Disord. 2022 Oct;66:104031. doi: 10.1016/j.msard.2022.104031. Epub 2022 Jul 4. Mult Scler Relat Disord. 2022. PMID: 35841716
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Costa LJ, Hari P, Berdeja JG, De Stefano V, Gay F, Hooper B, Bartlett M, Haltner A, Rosta E, Kumar S, Martin T, Mateos MV, Moreau P, Usmani SZ, Olyslager Y, Schecter JM, Roccia T, Garrett A, Lee S, Nesheiwat T, Pacaud L, Zhou C, Samjoo IA, Lin Y, Diels J, Valluri S, Weisel K. Costa LJ, et al. Among authors: samjoo ia. Curr Med Res Opin. 2022 Oct;38(10):1759-1767. doi: 10.1080/03007995.2022.2100651. Epub 2022 Aug 10. Curr Med Res Opin. 2022. PMID: 35815818
Letter in reply.
Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, Häring DA, Stoneman D, Klotz L, Adlard N. Samjoo IA, et al. J Comp Eff Res. 2021 Dec;10(17):1267-1269. doi: 10.2217/cer-2021-0203. Epub 2021 Oct 5. J Comp Eff Res. 2021. PMID: 34608814 Free article. No abstract available.
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T, Usmani SZ, Schecter JM, Vogel M, Jackson CC, Deraedt W, Tian H, Yeh TM, Banerjee A, Pacaud L, Garrett A, Haltner A, Cameron C, Van Sanden S, Diels J, Valluri S, Samjoo IA. Martin T, et al. Among authors: samjoo ia. Curr Med Res Opin. 2021 Oct;37(10):1779-1788. doi: 10.1080/03007995.2021.1953456. Epub 2021 Jul 23. Curr Med Res Opin. 2021. PMID: 34256668 Clinical Trial.
29 results